Non-high-density lipoprotein cholesterol: The forgotten therapeutic target

American Journal of Cardiology

Volumn 96, Issue 9 SUPPL. 1, 2005, Pages 59-64

  Maki, Kevin C ^a   Galant, Ron ^b   Davidson, Michael H ^b,c  

^a Provident Clinical Research   (United States)

^b RADIANT RESEARCH   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; HEALTH SURVEY; HUMAN; HYPERTRIGLYCERIDEMIA; MEDICAL ASSESSMENT; MYOPATHY; OUTPATIENT; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

EID: 27744452965     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.08.009     Document Type: Conference Paper

References (35)

1. G. Assmann, P. Cullen, H. Schulte The Munster Heart Study (PROCAM). Results of follow-up at 8 years Eur Heart J 19 suppl A 1998 A2 A11
2. M.A. Austin, J.E. Hokanson, K.L. Edwards Hypertriglyceridemia as a cardiovascular risk factor Am J Cardiol 81 4A 1998 7B 12B
3. National Cholesterol Education Program Expert Panel National Institutes of Health Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 2002 NIH Bethesda, MD NIH Publication 100 01-3670
4. J.L. Breslow Mouse models of atherosclerosis Science 272 1996 685 688
5. A.D. Sniderman, C.D. Furberg, A. Keech, J.E. Roeters van Lennep, J. Frohlich, I. Junger, G. Waddlius Apolipoproteins versus lipids as indicators of coronary risk and as targets for statin therapy Lancet 361 2003 777 780
6. W.T. Friedewald, R.I. Levy, D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
7. C.M. Ballantyne, T.C. Andrews, J.A. Hsia, J.H. Kramer, C. Shear ACCESS Study Group Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B effect of 5-hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels Am J Cardiol 88 2001 265 269
8. W. Lu, H.E. Resnick, K.A. Jablonski, K.L. Jones, A.K. Jain, W.J. Howard, D.C. Robbins, B.V. Howard Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes the Strong Heart Study Diabetes Care 26 2003 16 23
9. I. Shai, E.B. Rimm, S.E. Hankinson, G. Curhan, J. Manson, N. Rifai, M.J. Stampfer, J. Ma Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women potential implications for clinical guidelines Circulation 110 2004 2824 2830
10. Y. Cui, R.S. Blumenthal, J.A. Flaws, M.K. Whiteman, P. Langenberg, P.S. Bachorik, T.L. Bush Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality Arch Intern Med 161 2001 1413 1419
11. M.H. Davidson, K.C. Maki, T.A. Pearson, R.C. Pasternak, P.C. Deedwania, J.M. McKenney, G.C. Fonarow, D.J. Maron, B.J. Ansell, L.T. Clark, C.M. Ballantyne Results of the National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey implications for treatment under the recent NCEP Writing Group Recommendations Am J Cardiol 96 2005 556 563
12. S.M. Grundy, J.I. Cleeman, C.N.B. Merz, B. Brewer, L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith, N.J. Stone Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 110 2004 227 239
13. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) Lancet 244 1994 1383 1389
14. F.M. Sacks, M.A. Pfeffer, L.A. Moye Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
15. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
16. T.R. Pedersen, A.G. Olsson, O. Færgeman, J. Kjekshus Scandinavian Simvastatin Survival Study Group Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation 97 1998 1453 1460
17. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals a randomized placebo-controlled trial Lancet 360 2002 7 22
18. J. Shepherd, G.J. Blauw, M.B. Murphy PROSPER Study Group Pravastatin in elderly individuals at risk of vascular disease (PROSPER) a randomized controlled trial Lancet 360 2002 1623 1630
19. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, A.M. Skene Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators N Engl J Med 350 2004 1495 1504
20. M.J. Koren, D.B. Hunninghake ALLIANCE Investigators Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics J Am Coll Cardiol 44 2004 1772 1779
21. J.C. LaRosa, S.M. Grundy, D.D. Waters Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
22. M. Davidson, P. Ma, E.A. Stein, A.M. Gotto Jr, A. Raza, R. Chitra, H. Hutchinson Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia Am J Cardiol 89 2002 268 275
23. P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, E. Miller, V.A. Cain, J.W. Blasetto STELLAR Study Group Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) Am J Cardiol 92 2003 152 160
24. M.B. Katan, S.M. Grundy, P. Jones, M. Law, T. Miettinen, R. Paoletti Stresa Workshop Participants Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels Mayo Clin Proc 78 2003 965 978
25. A.E. Moreyra, A.C. Wilson, A. Koraym Effect of combining psyllium fiber with simvastatin in lowering cholesterol Arch Intern Med 165 2005 1161 1166
26. M.H. Davidson, M.R. Dicklin, K.C. Maki, R.M. Kleinpell Colesevelam hydrocholoride a non-absorbed, polymeric cholesterol-lowering agent Expert Opin Investig Drugs 9 2000 2663 2671
27. M.H. Davidson Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome Am J Cardiol 93 11A 2004 3C 11C
28. G. Schectman, J. Hiatt Dose-response characteristics of cholesterol-lowering drug therapies implications for treatment Ann Intern Med 125 1996 990 1000
29. M.H. Davidson Combination therapy for dyslipidemia safety and regulatory considerations Am J Cardiol 90 suppl 2002 50K 60K
30. M.H. Davidson, C.M. Ballantyne, B. Kerzner, L. Melani, P.T. Sager, L. Lipka, J. Strony, R. Suresh, E. Veltri Ezetimibe Study Group Efficacy and safety of ezetimibe coadministered with statins randomized, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia Int J Clin Pract 58 2004 746 755
31. A.S. Brown The use of combination therapy for dyslipidemia a lipid clinic approach Am J Cardiol 90 suppl 2002 44K 49K
32. A.M. Xydakis, C.M. Ballantyne Combination therapy for combined dyslipidemia Am J Cardiol 90 suppl 2002 21K 29K
33. T.A. Pearson, I. Laurora, H. Chu, S. Kafonek The lipid treatment assessment project (L-TAP) a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med 160 2000 459 467
34. J. McKenney Combination therapy for elevated low-density lipoprotein cholesterol the key to coronary artery disease risk reduction Am J Cardiol 90 suppl 2002 8K 20K
35. K.C. Maki Fibrates for treatment of the metabolic syndrome Curr Atheroscler Rep 6 2004 45 51